Our mission is to digitize, decode, and decipher human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer.



The Central Dogma Of Molecular Biology Is No Longer Simply Defined By The Static Nature Of DNA.


Microbial and human gene expression are now redefining how biological activities are viewed in relation to human health. The coupling of Viome’s metatranscriptomic and machine learning platform are revolutionizing the potential of precision therapeutics. Historically, traditional exploration of disease states have failed to include the significant impact of gut microbial populations on systemic inflammation and disease development. Offering health insights accumulated from hundreds of thousands of samples, Viome’s platform digitizes biological information and analyzes it to identify novel therapeutic targets.



DNA Strand

Our Unique Approach


We use a systems biology approach to deeply understand the origin and progression of disease using gene expression (mRNA) analysis with a state-of-the-art AI platform.





DNA

  • Rarely changes
  • Similar sequence in every organ & cell
  • Explains 5–10% of chronic diseases *

mRNA

  • Dynamic, constantly changing
  • Vastly different expression in the body
  • Explains 80% of chronic diseases



What is mRNA?


Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease.


Human Host + Invisible Microbiome = Complete Human

Tapping into Holistic Systems Biology


Viome sample analysis today



  • Stool metatranscriptomics (CLIA, Production)

  • Whole blood metatranscriptomics (CLIA, Production)

  • Saliva metatranscriptomics



Our technology is being used to digitize the human body through the collection of a variety available specimen types.



Viome utilizes the current meta-dataset of sequenced samples as a starting point for the investigation into various disease therapeutics.

Future



  • Throat metatranscriptomics

  • Vaginal metatranscriptomics

  • Cerebrospinal fluid metatranscriptomics
    & metagenomics

  • Nasopharyngeal metatranscriptomics

  • Synovial fluid metatranscriptomics &
    metagenomics

  • Urine metatranscriptomics

  • Plasma metatranscriptomics &
    metagenomics (normal collection & differential centrifugation)




Viome's
mRNA Platform


Increasing every day, Viome boasts access to an mRNA platform of more than a quarter million samples to generate and test hypotheses related to many chronic diseases and cancers. At our core, Viome focuses on establishing biological data trends that identify the patterns for optimal health. Our initiative integrates a robust dataset with innovative technology to determine causal relationships that evaluate and improve the current understanding of chronic diseases as we know them.


Metatranscriptomic
technology


Viome metatranscriptomic technology is only clinically validated metatranscriptomic technology in the world


Transparent Spacer Iamge
Metatranscriptomic technology

Insight to Intervention




PREVENTION

Our direct-to-consumer service analyzes gene expressions (mRNA) in order to provide individuals with health insights and precision nutrition to live a healthier life.


This platform of over 300,000 samples enables us to enhance our understanding of human biology as a system in order to develop predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases.


Clinical improvements in IBS, Diabetes, Depression & Anxiety.

DIAGNOSIS

Our predictive biomarkers provide us with the hypothesis to do clinical research and identify the signatures of chronic diseases, cancers, and aging.


Successfully developed over 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer, which represent over 50% of chronic diseases.


FDA Breakthrough Device Designation for oral & throat cancer to detect early-stage throat cancer and oral cancer with 95% specificity and 90% plus sensitivity.

THERAPEUTICS

The signatures found through diagnostics allow us to determine the mechanism of action to develop precision therapeutics in the form of drugs and vaccines.


Viome can determine drug effectiveness, including immunotherapy, which is dependent upon the gut microbiome.


Contracts with large pharma company to develop vaccines for colorectal cancer and an autoimmune disease.


Viome transforms samples into
effective Dx and Tx






Viome transforms samples into effective Dx and Tx

The ViOS Platform


Our ViOS platform, which includes advanced AI and System Biology, is applied to a proprietary dataset of 325,000 human samples and metadata with the objective to better understand pathogenic processes. With the ViOS platform, the precise characterization of human gene expression and human-microbial interactions enables the delivery of new diagnostics and treatments against chronic diseases.


The ViOS Platform

Viome has converted human biology into a big data problem


500 trillion RNA base pairs sequenced to date





Stool Microbiome



  • ~8.5M
    total microbial transcripts detected across all samples

  • ~11,400
    total microbial functions detected across all samples

  • ~7,800
    Total active species of bacteria, viruses, eukaryotes, archaea across all samples

  • ~80,000
    microbial transcripts detected per sample


  • ~3,000
    microbial functions detected per sample


  • >1,100
    microbial species detected per sample

Blood Transcriptome



  • ~19,500
    total human transcripts detected across all samples

  • up to ~14,000
    human transcripts detected per samples


Saliva Microbiome



  • >1.34M
    total microbial transcripts detected across all samples

  • >5,400
    total microbial functions detected across all samples

  • ~6,000
    total human transcripts detected per sample

  • >14,000
    total human transcripts detected across all samples

  • ~2,400
    total active taxa of microbes across all samples


Viome Molecular Services (VMS) Architecture




Viome Molecular Services (VMS) Architecture

Viome diagnostics:

FDA Breakthrough Device Designation
for mRNA Cancer Detect™






Viome diagnostics:  FDA Breakthrough Device Designation for mRNA Cancer Detect™

Viome Health Sciences R&D efforts focused on diseases with high unmet need





Viome Health Sciences R&D efforts focused on diseases with high unmet need

Utilizing Human Gene Expression And Microbial To Identify New Biomarkers For Targeted Therapeutics


Integration of new data insights accumulated from our consumer platform are readily evolving and expanding the current understanding of chronic disease prevention, prediction, diagnostics, prognostics, and therapeutics.


Utilizing Human Gene Expression And Microbial To Identify New Biomarkers For Targeted Therapeutics

Our Partners

Collaborations for therapeutics and opportunities to
improve speed, cost and risk for partners

Signed and in-process partnerships


Signed and in-process partnerships

Partnership opportunities


Drug discovery



  • Novel target identification

  • Better understanding of root causes of chronic disease

  • Unparalleled insight into healthy vs diseased individuals



Improve risk profile



  • Analyzing metatranscriptome provides insight into how body is responding to treatment

  • Prognostic and biomarker capabilities: excluding non-responders for higher success rates



Reduce costs & time



  • Virtual trail enrollment

  • Faster patient enrollment